COMPANY PROFILE

ALung Technologies

Explore full profile

Develops intra and extracorporeal gas exchange devices for the treatment of acute and chronic respiratory disorders

Pittsburgh, United StatesFounded 1997Health Tech & Medtech

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About ALung Technologies

ALung Technologies is a pioneering company in the medical device industry, specializing in the development of advanced solutions for treating respiratory failure. The company’s flagship product, the Hemolung Respiratory Assist System (RAS), offers a dialysis-like alternative or supplement to mechanical ventilation. This innovative system, originally developed at the University of Pittsburgh, directly removes carbon dioxide from the blood of patients suffering from acute respiratory failure, providing a critical lifeline for those in severe respiratory distress.

ALung primarily serves hospitals and healthcare providers who treat patients with acute respiratory conditions. The market it operates in is the medical device sector, specifically focusing on respiratory care. Given the increasing prevalence of respiratory diseases and the ongoing COVID-19 pandemic, the demand for effective respiratory support systems has surged, positioning ALung favorably within this growing market.

The company’s business model revolves around the development, manufacturing, and sale of its Hemolung RAS device. Revenue is generated through the direct sale of these devices to healthcare institutions, as well as through ongoing service and maintenance contracts. Additionally, ALung may engage in partnerships or licensing agreements to expand the reach and application of its technology.

ALung’s leadership team comprises experienced professionals in the medical and technological fields, supported by a board of directors and advisors who bring a wealth of industry knowledge. The company stays engaged with its stakeholders through regular updates in its newsroom, featuring news, user reports, webinars, and investment information.

In summary, ALung Technologies is at the forefront of respiratory care innovation, providing life-saving solutions to healthcare providers and patients. Its advanced medical devices, particularly the Hemolung RAS, address a critical need in the treatment of respiratory failure, making it a key player in the medical device market.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 1997
Headquarters: Pittsburgh, United States
Employees: 11
Open positions: None listed
Dealroom signal: 63.3/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Biotechnology, Critical medical care, Respiratory, Pulmonary, Non-Invasive medical devices and treatments, Spinout, Oil & Gas, Tech for Hospitals and Clinics, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	May 2022	$110M	$110M	LivaNova	↗
LATE VCOther financing	Aug 2021	$4.6M	$18M	LivaNova	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

ALung Technologies website traffic

Latest recorded traffic for ALung Technologies is 200 monthly website visits, down 70.6% over the last three months. ALung Technologies's team declined 57.7% over the past year.

Latest monthly visits200 3-month web change-70.6% 1-year team growth-57.7%

Monthly website visitsOct 2022–Jan 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ARArtiQHas developed AI-based software to help doctors save time and improve interpretation of lung function tests and diagnosis of lung diseases	Leuven, Belgium	Acquired	18	$1.1M	$4.5M
ESETISENSE SASDeveloped a non-invasive cardiac and respiratory flow-metering technology to monitor cardiorespiratory function in a non-invasive way	Lyon, France	Operational
BIBioBeatBioBeat develops a cutting-edge wearable for continuous non-invasive accurate medical-grade monitoring of vital signs, including continuous blood pressure, saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body t	Petah Tikva, Israel	Operational
EVEversensNon-invasive diagnostic solutions for breath analysis	Pamplona, Spain	Operational
OPOptellumDeveloping an artificial intelligence software platform to support clinicians in lung cancer nodule management	Oxford, United Kingdom	Operational
MBMedasense BiometricsMedasense is a developer of innovative medical devices and applications in the field of objective pain monitoring	Ramat Yishai, Israel	Operational
CMCheetah MedicalCheetah Medical is a device company developing non-invasive cardiac output and hemodynamic monitoring devices	Tel Aviv-Yafo, Israel	Acquired
OMOrnim MedicalNon-invasive patient monitoring devices for cerebral blood flow	Lod, Israel	Operational